RxDoctor Payments Data

Sanjay Gill, MD

Cardiovascular Disease · Chicago, ILNPI 1932361433

Payments from drug & device makers

$4,309in general payments, 2019–2025

Across 33 payments — averaging $130.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$3K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Novartis$569
  • Amgen$101
  • Novo Nordisk$25
  • E.r. Squibb & Sons, L.L.C.$25

What the payments were for

  • Speaking & faculty fees$3,27376%
  • Travel & lodging$1934%
  • Food & beverage$84420%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,309 in reported general payments places this provider in the 65th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$466,475
Medicare patients
669
Services billed
4,509

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban121$110,040
XareltoRivaroxaban92$80,365
EntrestoSacubitril/Valsartan99$72,922
JardianceEmpagliflozin92$67,704
BiktarvyBictegrav/Emtricit/Tenofov Ala12$56,289
OzempicSemaglutide21$31,135
RybelsusSemaglutide21$29,456
Repatha SureclickEvolocumab31$20,276
Praluent PenAlirocumab23$17,780
TradjentaLinagliptin11$10,905
Repatha SyringeEvolocumab14$8,635
Atorvastatin Calcium462$5,679
Rosuvastatin Calcium206$3,127
Bumetanide34$2,927
Metoprolol Succinate169$2,828

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$569$72,92299 claims
Novo NordiskOzempic, Rybelsus$25$60,59142 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →